Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
- Sponsor
- Pfizer
- Study ID
- NCT00143403
- Phase
- PHASE3
- Status
- Completed
Conditions
- Colorectal Neoplasms
- Liver Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan + 5 FU + folinic acid — DRUGirinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
- Folinic Acid + 5 FU — DRUGfolinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
Study Details
To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.
Key Dates
- Start date
- Dec 31, 2001
- Status verified
- Sep 2010
- Primary completion
- Feb 29, 2008
- Completion
- Sep 30, 2009
Study Design
- Enrollment
- 321 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
- Active Comparator: 2
Primary Outcome Measure
Disease Free Survival (DFS) [ Time Frame: last tumor assessment date or cut-off date, whichever is earlier. ]
Related Studies
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerPHASE3 · Recruiting · Surgimab · Duarte, California
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsPHASE1 · Recruiting · National Cancer Institute (NCI) · Fairway, Kansas